META HEALTH LIMITED

(formerly known as Metal Component Engineering Limited) (Incorporated in the Republic of Singapore) (Company Registration No. 198804700N)

PROFIT GUIDANCE FOR THE HALF YEAR ENDED 30 JUNE 2022

The board of directors (the "**Board**") of Meta Health Limited (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce that, following a preliminary review of the Group's unaudited consolidated financial results for the half year ended 30 June 2022 ("**HY2022**"), the Group is expected to report a net loss for HY2022.

The net loss for HY2022 was mainly due to a decrease in sales revenue resulting from (i) lockdown in Shanghai for close to two months due to the COVID-19 pandemic that severely impacted the sales in China, (ii) shortage of IC chips that affected the Group's customers' demands, and (iii) uncertainty in Europe caused by the war in Ukraine and the on-going Sino-US trade war.

The Group is in the process of finalising its unaudited consolidated financial results for HY2022. Further details of the Group's financial performance for HY2022 will be disclosed when the Company announces the Group's unaudited consolidated financial results for HY2022 on or before 14 August 2022.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities and are advised to read this announcement and any further announcements by the Company carefully. When in doubt, shareholders and potential investors are advised to seek independent advice from their professional advisor before trading or making any investment decision on the Company's securities.

BY ORDER OF THE BOARD

Lee Wei Hsiung Mak Peng Leong, Philip Company Secretaries 18 July 2022

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor ("**Sponsor**"), ZICO Capital Pte. Ltd., in accordance with the Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr Alex Tan, Chief Executive Officer, ZICO Capital Pte. Ltd., at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.